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Background: Oocyte donation is a medical technique used principally for woman with ovarian failure. Optimizing
donor recruitment is essential to obtain the best results with this technique. Understanding how donor parameters
influence outcome for the recipients is fundamental. The aim of this study was to determine whether clinical and/
or biological parameters in the donors influence the chance of pregnancy in recipients. Our objective was also to
verify whether the outcomes of controlled ovarian stimulation (COS) are predictive of pregnancy in the recipients.
Methods: A retrospective observational study was conducted in the Department of Reproductive Medicine in the
Lille University Hospital. Between September 2005 and April 2014, COS was performed in 145 donors for 308
recipients’ cycles. We compared the cycles whose outcome was pregnancy to the cycles without pregnancy.
Quantitative variables were compared using the nonparametric Mann–Whitney test. Qualitative variables were
compared using a Chi-2 test or Fisher exact test, according to the numbers. Covariance analysis was performed to
adjust for potential confounding factors.
Results: The donors who produced at least one pregnancy had a mean baseline serum anti-Müllerian hormone
(AMH) level significantly higher than those who did not (p = 0.001). The mean antral follicle count did not differ
between the 2 groups. After covariance analysis controlling for the number of couples attributed to a given donor,
this difference remained significant (p = 0.029). Mature follicle number, estradiol serum level at the trigger day,
number of mature oocytes and embryo number were significantly higher in the donors who produced pregnancy.
Conclusion: Serum AMH level is associated with pregnancy outcome after oocyte donation.
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Oocyte donation is a medical technique used principally
for women with ovarian failure. At the end of 2011 in
France, 1,806 couples were waiting for oocyte donation,
whereas only 402 couples received a donation the same
year. Recently, this activity increased slightly but insuffi-
ciently to address all requests, resulting in a long delay
for recipient couples. Optimizing donor recruitment is
essential to obtain the best results with this technique.* Correspondence: sophie.jonard@chru-lille.fr
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come of the recipients is fundamental. Many clinical or
biological parameters can influence ART results such as
the woman’s age, ovarian reserve and oocyte quality.
Anti-Müllerian hormone (AMH) is an interesting bio-
logical marker because it reflects ovarian reserve. It can
also predict ovarian response to controlled ovarian
stimulation (COS). However the value of this biological
marker to predict pregnancy in oocyte donation is
unknown.
The aim of this study was to determine whether clin-
ical and/or biological parameters in the donor influence
the chance of pregnancy in recipients. We also verified
whether the COS outcomes are predictive of pregnancyle is distributed under the terms of the Creative Commons Attribution 4.0
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in pregnancy with cycles which did not result in
pregnancy.
Methods
All oocyte donation cycles performed in the Department
of Reproductive Medicine in the Lille University Hospital
between September 2005 and April 2014 were analyzed
retrospectively. Oocyte donation cycles were performed in
accordance with the bioethics law. This study was
approved by the institutional Review Board of Lille
University Hospital. All patients gave their informed con-
sent before oocyte donation.
Population
All potential oocyte donors underwent consultation with
a referring physician of the Department. They were
under the age of 38 years and had at least one child.
About 25 % of the donors were altruistic. The other do-
nors were relatives (i.e., recruited by recipient couple)
but we performed anonymous cross-donations.
Donors with hereditary pathology, abnormal karyotype,
body mass index (BMI) > 35 kg/m2, AMH< 1.5 ng/mL,
AFC < 10 and/or abnormal serology were rejected. The
donors underwent a rigorous clinical evaluation in search
of contraindication to oocyte donation, including heredi-
tary pathology. On the day of the consultation, ovarian re-
serve was evaluated by serum AMH assay (complemented
by serum FSH and estradiol assays between days 2 and 5
of a spontaneous cycle), and antral follicle count (AFC,
sum of both ovaries) by transvaginal ultrasonography
(Voluson E8 Expert, GE Healthcare). Karyotype, psycho-
logical evaluation and HIV1-2, HTLV, HBV, HCV, syphilis,
and CMV serology completed the evaluation.
Serum AMH levels were assessed using the second
generation enzyme immunoassay AMH-EIA (ref. A16507)
provided by Beckman Coulter Immunotech (Villepinte,
France).
For matching donors and recipients, phenotypic char-
acteristics (geographic origin, color of skin, eyes and
hair, weight, height) and blood group were registered. A
donor was allocated to one, two or three recipient(s)
according to her ovarian reserve and the number of
oocytes at the puncture.
Donor cycle
All donors COS was performed in the department of
Reproductive Medicine in University Hospital. One cycle
was performed by one donor for one, two or three
recipient’s couples.
The recipients received endometrial preparation syn-
chronously to the donor stimulation using hormonal re-
placement treatment, and GnRH agonists if the recipient
still cycled. Recipients were started on oral micronizedestradiol (6 mg /day). Evaluation of endometrial thickness
was performed at D14 and considered satisfactory
if ≥ 7 mm. Vaginal micronized progesterone (800 mg/day)
was initiated on the evening of donor oocyte retrieval.
A long agonist protocol was used for donors’ stimulation
between September 2005 and December 2011. From
January 2012, an antagonist protocol was used. COS was
performed with gonadotropins, individually adjusted
based on AFC, baseline serum AMH level, age and body
mass index (BMI) values, and adapted during stimulation
according to ultrasound findings and estradiol levels.
When there were at least 2 follicles measuring > 18 mm
mean diameter, ovulation was triggered either by sub-
cutaneous recombinant hCG 0.25 mg (Ovitrel*; Merck
Serono) or by GnRH agonist (triptoreline) 0.2 mg
(Decapeptyl; Ipsen Pharma) in case of antagonist protocol.
Follicles were aspirated transvaginally with ultrasound
guidance 35 to 36 h thereafter. Fertilization was per-
formed by intracytoplasmic sperm injection (ICSI) with
the sperm of the spouse. Embryo transfer of 1 or 2
embryos was performed at days 2 or 3. If the embryo
quality was sufficient, surplus embryos were frozen. The
transfer of frozen embryos was performed under hormo-
nal replacement protocol (oral estrogen and intravaginal
progesterone) identical to the fresh transfer. Fourteen days
after the embryo transfer, serum β-HCG level was mea-
sured. Transvaginal ultrasonography was performed at 5–6
weeks gestation to assess the presence of a gestational sac.
Data collection
Data on age, BMI, parity, smoking, serum AMH levels
and AFC were collected.
For each donor cycle, total dose of gonadotropins,
duration of stimulation, number of follicles > 15 mm and
estradiol serum level the day of trigger and the number
of collected oocytes were recorded.
Clinical pregnancy was defined by the presence of an
intrauterine gestational sac with heart activity on ultra-
sound performed at 5–6 weeks of amenorrhea.
Birth was defined as delivery of a child after at least
24 weeks of amenorrhea.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS 22.0 for Windows).
Quantitative variables were compared using the non-
parametric Mann–Whitney test. Qualitative variables
were compared using a Chi-2 test or Fisher exact test,
according to the numbers. Covariance analysis was per-
formed to adjust for potential confounding factors.
Results
Between September 2005 and April 2014, 145 donors
underwent COS in our department for 308 recipients.
Table 1 Clinical, biological and ultrasound characteristics of
oocyte donors
Age (years)a 32 (23–37)a
Child numbera 2 (1–4)a
BMI (kg/m2)a 23 (I8,5–31)a
AMH (ng/mL)a 3.9 (1,8–9.7)a
Antral follicle court (sum of both ovaries)a 20 (10–42.5]a
Smokerb 28 %
Overweight {BMI≥25kg/m2)b 38 %
aMedian [5th percentile-55th percentile]
bPercent
Table 3 Comparisons between the donors achieving pregnancy
and the others
Pregnancy No pregnancy P
Number of oocyte donors 85 60
Age (years)a 31 [23–37] 32 [24.9–37] 0.425
BMI ≥ 25 27.1 % 45.7 % 0.064
Smokers 37.3 % 37.5 % 0,897
Number of recipients
per donora
3 [1–3] 2 [1–4] 0,001
Child number of the
donora
2 [1–4] 1.9 [1–3.55] 0.096
AMH (ng/mL)a 4,48 [2.23–9.96] 3.15 [1.65–8.6] 0,001
Antral follicle count
(sum of both ovaries)
20 [11–49] 19 [10–36] 0.095
Number of mature folliclesb 16.6 ± 7.4 11.5 ± 5.2 <0.001
Duration of stimulation (days)b 12.1 ± 1.7 12.4 ± 1,8 0.26
Estradiol on the trigger
day (pg/mL)b
2429 ± 1136 1694 ± 10.1 <0.001
Total dose of
gonadotropins (UI)b
2650 ± 856 3315 ± 959 <0.001
Number of mature oocytesb 11.3 ± 6.1 7.2 ± 4.9 <0.001
Number of embryosb 7.5 ± 4.2 4 ± 3.2 <0.001
aMedian [5th percentile–95th percentile]
bMean ± standard deviation
Table 4 Results of recipient cycles
Value
Number of recipient cycles 308
Number of transfers 418
Number of pregnancies 133
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stimulation syndrome and 2 because of absence of
ovarian response. For seven donors, we performed no
embryo transfer due to poor oocyte or embryo quality.
Over a period of 8 years, 418 transfer cycles were per-
formed: 288 with fresh embryos (69 %) and 130 with fro-
zen embryos (31 %).
Clinical, biological and ultrasound characteristics of
the donors are summarized in Table 1. 28 % of donors
were overweight or obese (BMI = 25-35 kg/m2) and 38 %
were smokers.
The outcomes of the 145 donors COS are shown in
Table 2. The donors whose eggs resulted in at least one
pregnancy (n = 85) had serum AMH level significantly
higher than those who did not (n = 60) (p = 0.001)
(Table 3). After covariance analysis controlling for the
number of couples attributed to a donor, the difference
remained significant (p = 0.029). However, receiver oper-
ating characteristic (ROC) curve analysis showed that
for pregnancy outcome, donors’ AMH values yielded a
low area under the curve (0.665) [CI: 057–0.76], insuffi-
cient to reach a predictive threshold. For example, a
threshold at 5 ng/mL gave a specificity of 75 % but a
sensitivity of only 41 %. Concerning the stimulation pa-
rameters, mean mature follicle number, serum estradiol
level at the trigger day, number of mature oocytes and
embryo number were significantly higher in the donors
who achieved pregnancy. The mean total dose of usedTable 2 Outcomes of the of the 145 donor’s COS
Mean (SD)
Number of mature follicles 14.5 (±7)
Duration of stimulation (days) 12.2 (±1.7)
Estradiol on the trigger day (pg/mL) 2128 (±1142)
Total dose of gonadotropins (Ul) 2926 (±955)
Number of mature oocytes 9.6 (±6)
Number of embryos 6 (±4.1)
Pregnancies rate per donor 90 %
Birth rate per donor 70 %gonadotropins was higher in donors without pregnancy.
Conversely, stimulation duration did not differ signifi-
cantly between the two groups (Table 3).
The results of recipient cycles are summarized in
Table 4. After the 145 donors’ COS, 1,380 mature oocytes
were given to 308 recipients (mean ± SD: 4.5 ± 1.7 oocytes
per recipient and per cycle). After fertilization by ICSI,
870 embryos were obtained, i.e. 2.9 ± 1.7 embryos per
recipient. Among the embryos, 77 % were transferred.Number of miscarriages 42
Number of births 108
Number of oocytes per recipient per cyclea 4,48 ± 1.68
Number of transferred embryos per cyclea 1.59 ± 0.51
Implantation rate 23 %
Pregnancy rate per transfer 31.8 %
Pregnancy rate per cycle (fresh and thawed embryos) 43.2 %
Birth rate per transfer 25.1 %
Miscarriage rate 31.6 %
Birth rate per cycle (fresh and thawed embryos) 35.1 %
aMean ± standard deviation
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27 % after thawing. A mean of 2.3 embryos were trans-
ferred to recipient per donor COS (immediately and after
thawing), with an average of 1.6 embryos per transfer.
Discussion
The aim of this study was to identify whether features in
the oocyte donors were associated with pregnancy in the
recipient.
We did not observe an influence of donor’s age on
pregnancy outcome, probably because most of the do-
nors were young. Indeed, only 13.1 % of our donors
were over 35 years old. In the literature, most of studies
did not observe influence of donor’s age on oocyte dona-
tion outcome [1–4]. The use of ovarian reserve markers,
such as serum AMH, to select the donors with a good
potential ovarian response lead to refusal of older donors
who more frequently have an AMH serum level lower
than 1.5 ng/mL. Therefore, the age effect on pregnancy
outcome is less important than in the setting of IVF in
infertile women using their own oocytes.
We found a trend for a negative influence of donor’s
BMI on pregnancy outcome. Overweight and obesity are
responsible for impaired oocyte quality [5]. However,
our results were not statistically significant and pub-
lished data are controversial. We excluded donors
having a BMI higher than 35 kg/m2, because of the diffi-
culties and the risks linked to COS and puncture.
The high predictive value of serum AMH level on re-
sponse to COS has already been reported [6, 7]. Our
study was in agreement with other series of donors
showing a good correlation between serum AMH level
and ovarian response: number of collected oocytes, total
dose of gonadotropins used and serum estradiol level
the day of trigger [8–14]. Thus, serum AMH level is a
reliable marker to obtain the largest number of oocytes
while trying to limit the occurrence of ovarian hyper-
stimulation syndrome [8–12]. The minimum threshold
of AMH at 1.5 ng/mL, that we used in our center, has
been reported to provide a sensitivity of 86 % and a
specificity of 78 % to predict a sufficient ovarian
response [8].
In our study, the AFC was not different between the
donors who achieved a pregnancy and those who did
not, although serum AMH level was higher in the
former. To our knowledge, this is the first study report-
ing a significantly higher AMH level in donors that pro-
duced a pregnancy compared with those who did not.
Moreover, this difference persisted after adjustment for
the number of recipients assigned to each donor, which
would be a bias via the increased number of transfers.
Previously, several authors have shown that serum AMH
level was associated with oocyte quality, that could explain
the association of AMH with pregnancy occurrence[15–19]. A recent meta-analysis reported a strong associ-
ation between serum AMH level and the occurrence of
live birth after in vitro fertilization, but the predictive
value of AMH was very low [20]. Similarly in our study,
we were not able to identify an AMH threshold value that
could predict with sufficient power the outcome of oocyte
donation. Indeed, the area under the ROC curve was low
(AUC= 0.665; IC: 0.57-0.76). This is confirmed by five
other studies [8, 9, 11, 13, 14]. For example, Riggs et al.
found an AUC at 0.559 [8]. Thus, serum AMH level is as-
sociated with the outcome of an oocyte donation, but its
predictive value is poor.
Conclusion
Our study updates the importance of AMH to evaluate
ovarian reserve of oocyte donors. AMH was shown to
be correlated to the donor’s response to COS and to the
number of oocytes allocated to one or more recipients.
Although serum AMH level is associated with pregnancy
outcome after oocyte donation, its predictive value is
insufficient to be used to select donors by itself.
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